<DOC>
	<DOC>NCT00333788</DOC>
	<brief_summary>The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581]. It will also assess the effect of subcutaneous CDP870 400 mg on direct cost parameters.</brief_summary>
	<brief_title>Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients having completed study C87042 [NCT00308581] (previously treated with infliximab) Subject withdraw from C87042 [NCT00308581] study Subject who received treatment other than certolizumab pegol and other than medications permitted in C87042 [NCT00308581] study Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment Female patients of childbearing age who are NOT practicing (in the Investigator's opinion) effective birth control. All female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Certolizumab pegol</keyword>
	<keyword>CDP870</keyword>
	<keyword>Cimzia</keyword>
</DOC>